Clinicians Still Have Concerns Regarding Melanoma Treatment Options
the Cancer Therapy Advisor take:
Two new targeted systemic therapies have been recently introduced as possible treatment options for advanced melanoma, according to an article published online in the European Journal of Cancer Care.
Participants in this study included 343 oncologists who completed online surveys between August and November 2012 (in 11 countries) and March and April 2013 (in another country), following the introduction of the two new treatment agents.
The authors analyzed the results of the surveys and found 23 clinical issues of concern across all countries. Of these 23 issues, the most common were identified as being drug toxicity and tolerability. The second most common was limited treatment effectiveness, followed by limited treatment options.
The findings of the study state that clinical professionals still have concern regarding the limitations of treatment options available to patients despite the promise of two new agents for treating advanced melanoma.
Two new targeted systemic therapies have been recently introduced as possible treatment options for advanced melanoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML